Hit Me With Your Best Shot: Long-Acting Therapies to Improve HIV Viral Suppression

In their article, Gandhi and colleagues report on a project that offered long-acting injectable cabotegravir-rilpivirine to people with HIV with viral suppression who wished to switch to long-acting injectable therapy and people with HIV viremia who struggled with daily pill adherence but expressed willingness to visit the clinic for regular injections. The editorialists discuss the findings, advocate for consideration of long-acting injectable therapy for all patients with HIV, and challenge us to invest in care models that prioritize the most vulnerable people.